<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594176</url>
  </required_header>
  <id_info>
    <org_study_id>CL-064-IV-01 (IMR-062)</org_study_id>
    <nct_id>NCT02594176</nct_id>
  </id_info>
  <brief_title>Study of FLEXISEQ® for Treatment of Osteoarthritis of the Knee in NSAID-compromised Patients</brief_title>
  <acronym>OANIT</acronym>
  <official_title>A Randomised, Double-blind, Placebo Controlled Study of Topical FLEXISEQ® for the Treatment of Osteoarthritis of the Knee in Patients Contraindicated for or With Clinical Intolerance to NSAIDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pro Bono Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Medical Research - Partner GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pro Bono Bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective To substantiate the efficacy of 2.2 g FLEXISEQ® for the treatment of pain&#xD;
      related to osteoarthritis (OA) of the knee in patients contraindicated for or with clinical&#xD;
      intolerance to NSAIDs.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To substantiate the efficacy of 2.2 g FLEXISEQ® for the treatment of stiffness and&#xD;
           improvement of joint function in patients contraindicated for or with clinical&#xD;
           intolerance to NSAIDs and with OA of the knee.&#xD;
&#xD;
        -  To substantiate safety and tolerability of 2.2 g FLEXISEQ® in patients contraindicated&#xD;
           for or with clinical intolerance to NSAIDs and with OA of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This post marketing clinical follow-up, randomised, double-blind study comparing the efficacy&#xD;
      and tolerability of topical FLEXISEQ® with placebo for the treatment of osteoarthritis of the&#xD;
      knee in patients contraindicated for or with clinical intolerance to NSAIDs and with OA of&#xD;
      the knee will have a total individual treatment period of 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC pain score</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline to final visit of the average of the WOMAC pain subscale scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Change (PGIC)</measure>
    <time_frame>3 months</time_frame>
    <description>PGIC-Score at final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC function score</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline to final visit of the average of the WOMAC function subscale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC stiffness score</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline to final visit of the average of the WOMAC stiffness subscale scores</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>3 months</time_frame>
    <description>Frequency of treatment emergent AEs per treatment group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.2 g FLEXISEQ® twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2.2 g placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLEXISEQ®</intervention_name>
    <description>applicable gel</description>
    <arm_group_label>Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>applicable gel</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent prior to any study-mandated procedure&#xD;
&#xD;
          2. Willing and able to comply with study requirements&#xD;
&#xD;
          3. Outpatients with an age ≥ 50 (starting from the day after the 50th birthday)&#xD;
&#xD;
          4. Patient for whom their knee pain is the worst pain in the body and is able to identify&#xD;
             the predominantly painful (target) knee&#xD;
&#xD;
          5. Patient has a primary diagnosis of Functional Class I-III OA of the target knee and&#xD;
             patient meets American College of Rheumatology (ACR) clinical classification criteria&#xD;
             for osteoarthritis of the knee&#xD;
&#xD;
          6. NSAID contraindicated or clinically intolerant&#xD;
&#xD;
          7. Females able to conceive (including peri-menopausal women who have had a menstrual&#xD;
             period within 1 year) must be using appropriate birth control (defined as a method&#xD;
             which results in a low failure rate&#xD;
&#xD;
          8. If female and able to conceive, patient has a negative urine pregnancy test at&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General exclusion criteria&#xD;
&#xD;
               1. Planned treatment or treatment with another investigational drug within 30 days&#xD;
                  prior to randomisation&#xD;
&#xD;
               2. Patients who are inmates of psychiatric wards, prisons, or other state&#xD;
                  institutions&#xD;
&#xD;
               3. Investigator or any other team member involved directly or indirectly in the&#xD;
                  conduct of the clinical study&#xD;
&#xD;
               4. Pregnancy or lactation&#xD;
&#xD;
               5. Any planned or expected hospitalisation within the study period&#xD;
&#xD;
               6. Patients not able to perform the WOMAC test (physically handicapped or immobile&#xD;
                  patient, e.g. wheel-chair bound)&#xD;
&#xD;
               7. Any health condition which, in the investigator's opinion means the patient is&#xD;
                  likely to be unable to complete the 12 week study Medical history related&#xD;
                  exclusion criteria&#xD;
&#xD;
               8. Skin lesions or dermatological diseases in the treatment area&#xD;
&#xD;
               9. Extreme obesity (BMI &gt; 35)&#xD;
&#xD;
              10. Uncontrolled hypertension&#xD;
&#xD;
              11. Requiring dialysis&#xD;
&#xD;
              12. Hepatocellular insufficiency preventing use of paracetamol&#xD;
&#xD;
              13. Alcohol abuse&#xD;
&#xD;
              14. Intolerance to paracetamol&#xD;
&#xD;
              15. Malignancy within the past 2 years&#xD;
&#xD;
              16. Morbus Meulengracht/Gilbert Syndrome&#xD;
&#xD;
              17. Neurological or psychiatric disorders compromising pain rating by the patient,&#xD;
                  such as but not limited to depressive disorders, schizophrenia or epilepsy&#xD;
&#xD;
              18. Any other pain condition requiring acute or chronic use of pain medication that&#xD;
                  cannot be discontinued at screening&#xD;
&#xD;
              19. Inflammatory arthritis including rheumatoid arthritis, psoriatic arthritis, gout,&#xD;
                  pseudo gout, systemic lupus erythematodes, ankylosing spondylitis, mixed&#xD;
                  connective tissue disease&#xD;
&#xD;
              20. Symptomatic hip OA ipsilateral to the target knee&#xD;
&#xD;
              21. Severe (axial misalignment &gt; 10°), uncorrected genu vara and genu valga&#xD;
&#xD;
              22. Arthroscopy of the target knee within 6 months prior or during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Rother, MD</last_name>
    <role>Study Director</role>
    <affiliation>International Medical Research - Partner GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Rother, MD</last_name>
    <phone>+49 89 858360925</phone>
    <email>m.rother@imr-partner.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilka Rother, MD</last_name>
    <phone>+49 89 858360911</phone>
    <email>i.rother@imr-partner.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IMR-Site #1-30</name>
      <address>
        <city>Gräfelfing</city>
        <state>Bavaria</state>
        <zip>82166</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Rother, MD</last_name>
      <phone>+49 89 858360925</phone>
      <email>m.rother@imr-partner.de</email>
    </contact>
    <contact_backup>
      <last_name>Ilka Rother, MD</last_name>
      <phone>+49 89 858360911</phone>
      <email>i.rother@imr-partner.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Conaghan PG, Dickson J, Bolten W, Cevc G, Rother M. A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford). 2013 Jul;52(7):1303-12. doi: 10.1093/rheumatology/ket133. Epub 2013 Mar 28.</citation>
    <PMID>23542612</PMID>
  </reference>
  <reference>
    <citation>Rother M, Conaghan PG. A randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J Rheumatol. 2013 Oct;40(10):1742-8. doi: 10.3899/jrheum.130192. Epub 2013 Sep 1.</citation>
    <PMID>23996292</PMID>
  </reference>
  <reference>
    <citation>Kneer W, Rother M, Mazgareanu S, Seidel EJ; European IDEA-033 study group. A 12-week randomized study of topical therapy with three dosages of ketoprofen in Transfersome® gel (IDEA-033) compared with the ketoprofen-free vehicle (TDT 064), in patients with osteoarthritis of the knee. J Pain Res. 2013 Oct 25;6:743-53. doi: 10.2147/JPR.S51054. eCollection 2013.</citation>
    <PMID>24187510</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Pain</keyword>
  <keyword>NSAID</keyword>
  <keyword>Sequessome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

